Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Levonorgestrel Releasing Intrauterine System

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Levonorgestrel Releasing Intrauterine System. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-020922-16 Sponsor Protocol Number: BAY 86-5028/15105 Start Date*: 2011-03-01
    Sponsor Name:Bayer Healthcare AG
    Full Title: International, prospective, double-blind, 3-arm comparative, randomized, placebo controlled phase IV study on the effect of counseling and either tranexamic acid or mefenamic acid or placebo, on th...
    Medical condition: Management of bleeding/spotting in women using the levonorgestrel-releasing intrauterine system (Mirena) for contraception.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046883 Vaginal bleeding LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002291-42 Sponsor Protocol Number: 308901 Start Date*: 2005-03-17
    Sponsor Name:Schering AG
    Full Title: Multi-center, open, randomized, dose finding phase II study to investigate for a maximum of three years ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) releasing in vitro 12 ...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010808 LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) SE (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001552-37 Sponsor Protocol Number: RG07-066(FormerlyHTA02/06/02) Start Date*: 2008-07-25
    Sponsor Name:University of Birmingham
    Full Title: Effectiveness and Cost-effectiveness of Levonorgestrel containing Intrauterine system in Primary care against Standard Treatment for menorrhagia
    Medical condition: Menorrhagia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002350-22 Sponsor Protocol Number: LR-201 Start Date*: 2020-01-14
    Sponsor Name:Chemo Research S.L.
    Full Title: Multi-center, phase 2, open-label, randomized clinical trial to evaluate the inhibition of ovulation of 3 dosing strengths of levonorgestrel (LNG) vaginal delivery system (VDS), releasing during 28...
    Medical condition: Women´s healthcare (Contraception, inhibition of ovulation)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10010808 Contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001984-21 Sponsor Protocol Number: 3/013/13 Start Date*: 2013-09-11
    Sponsor Name:University of Aberdeen & NHS Grampian
    Full Title: PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-004956-23 Sponsor Protocol Number: IIBSP-DIU-2015-85 Start Date*: 2016-02-25
    Sponsor Name:Institut de Recerca HSCSP
    Full Title: COLIBRI STUDY, Cooper and Levonorgestrel Intrauterine Device (IUD) Barcelona Research Initiative. A randomized controlled trial to compare the menstrual bleeding profile among cooper and 13,5mg lev...
    Medical condition: Contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003980-74 Sponsor Protocol Number: BAY1007626/15731 Start Date*: 2015-06-17
    Sponsor Name:Bayer AG
    Full Title: Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system releasing BAY 1007626,...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10010809 Contraception NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000612-17 Sponsor Protocol Number: HyperplasiLNG Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital of North Norway
    Full Title: Significance of intrauterine progestogen therapy in endometrial proliferative conditions
    Medical condition: Endometrial cancer has presently become the most frequent gynaecologic malinancy in the Western World and the incidence is still increasing. In Norway a 50% increase in occurence has been observed ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003367-19 Sponsor Protocol Number: NUC-5/PSC Start Date*: 2017-09-28
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
    Medical condition: Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of assumed autoimmune, but finally unidentified etiology, characterized by a chronic inflammatory and ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Ongoing) GB (GB - no longer in EU/EEA) HU (Ongoing) LT (Ongoing) FI (Ongoing) CZ (Prematurely Ended) BE (Completed) DK (Ongoing) NL (Ongoing) FR (Ongoing) SE (Ongoing) NO (Ongoing) PL (Not Authorised) IE (Prematurely Ended) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010824-25 Sponsor Protocol Number: DSHNHL 2008-R6 Start Date*: 2010-04-12
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation-Hämatologie und Onkologie mbH
    Full Title: Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-d...
    Medical condition: Patients with relapsed or primary progressive aggressive non-Hodgkin's lymphoma. These lymphomas comprise: 1. Follicular lymphoma grade III (FL III°) 2. Diffuse large B cell lymphoma (DLBCL), all v...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000167-69 Sponsor Protocol Number: AIC649-02-II-01 Start Date*: 2021-06-30
    Sponsor Name:AiCuris Anti-Infective Cures AG
    Full Title: A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AIC649 in the treatment of otherwise healthy subjects with asymptomatic or mildly symptomatic SARS-CoV-2 ...
    Medical condition: asymptomatic or mildly symptomatic SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084467 Asymptomatic SARS-CoV-2 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007246-60 Sponsor Protocol Number: NLG-MCL4(LENA-BERIT) Start Date*: 2009-06-23
    Sponsor Name:Nordic Lymphoma Group
    Full Title: Lenalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026805 Mantle cell lymphoma stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026804 Mantle cell lymphoma stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026803 Mantle cell lymphoma stage II PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000087-15 Sponsor Protocol Number: CRd Start Date*: 2012-03-30
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE...
    Medical condition: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013423-31 Sponsor Protocol Number: TEXO0309 Start Date*: 2010-01-21
    Sponsor Name:Medizinische Universität Innsbruck, Universitätsklinik für Innere Medizin I
    Full Title: Phase I/II study of lenalidomide and Cetuximab in patients with advanced solid tumors
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    9.1 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001296-20 Sponsor Protocol Number: MITOCET Start Date*: 2013-12-20
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Randomized Phase IV Trial to Compare Cetuximab with Concomitant Radiation Therapy with Concomitant Mitomycin-C and 5-FU with Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of The H...
    Medical condition: Locally advanced squamous cell carcinomas of head and neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010947-15 Sponsor Protocol Number: LENALIDOMIDE-MALT Start Date*: 2010-02-25
    Sponsor Name:MUW, Klinik für Innere Med. I, Onkologie
    Full Title: PHASE II TRIAL OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)
    Medical condition: MALT Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003115-21 Sponsor Protocol Number: 2018/2798 Start Date*: 2019-02-19
    Sponsor Name:Gustave Roussy
    Full Title: A phase II whole exoMe sequencing-bAsed baskeT trIal for combination therapy with durvaLumab (anti-PDL1) (MEDI4736) anD tremelimumAb (anti-CTLA4) in patients with metastatic solid tumors
    Medical condition: Metastatic colorectal adenocarcinoma (without microsatellite instability (not MSI)), triple negative breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066350 Adenocarcinoma of the gastrooesophageal junction LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005818-10 Sponsor Protocol Number: AGMT_MALT-2 Start Date*: 2012-05-02
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: PHASE II TRIAL OF RITUXIMAB (MABTHERA®) PLUS LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)
    Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002768-32 Sponsor Protocol Number: MM03 Start Date*: 2009-06-08
    Sponsor Name:Freistaat Bayern
    Full Title: A prospective phase I/II, one-arm, one-stage multi-center, open label study of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan in p...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000682-32 Sponsor Protocol Number: PAUF-I Start Date*: 2022-02-16
    Sponsor Name:Prestige Biopharma Limited
    Full Title: A First in human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer
    Medical condition: Advanced and/or metastatic pancreatic adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA